Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

Background Despite the use of aspirin, there is still a risk of ischaemic events after
percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to …

Atherothrombosis is a systemic disease that often involves the coronary, cerebrovascular,
and peripheral arterial circulations. The presence of multiple risk factors, even in …

Objectives. Stroke is a common condition after a transient ischemic attack (TIA) or minor
ischemic stroke (IS). Adding clopidogrel to aspirin may yield more beneficial outcomes than …

Objectives: The goal of this study was to determine whether there is a relationship between
aspirin dose and the potent antiplatelet agent prasugrel in the TRITON–TIMI 38 (Trial to …

In “Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to
Antiplatelet Monotherapy for the Prevention of Vascular Events,” Bowry et al 1 found that …

Background: Aggressive antiplatelet treatment is currently an established practice in patients
with coronary artery disease. Objective: This article discusses the evidence from clinical …

Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …

Background—The risk of ischemic events is high, both early and late after acute coronary
syndromes (ACS). We examine the benefits and risks associated with the use of adding …